|
| Status |
Public on Dec 03, 2010 |
| Title |
G2019S-AZO |
| Sample type |
RNA |
| |
|
| Source name |
fibroblasts
|
| Organism |
Homo sapiens |
| Characteristics |
cell type: patient derived fibroblast cells
disease status: control
lrrk2 mutation: G2019S
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was extracted with Trizol reagent. Quality control was performed with Agilent Bioanalyser.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared with the Ambion MessageAmp kit for Illumina arrays
|
| |
|
| Hybridization protocol |
Standard Illumina hybridization protocol
|
| Scan protocol |
Standard Illumina scanning protocol
|
| Description |
CN
|
| Data processing |
The data were normalised using quantile normalisation with Beadstudio v3.2
|
| |
|
| Submission date |
Nov 23, 2010 |
| Last update date |
Nov 23, 2010 |
| Contact name |
Marcel van der Brug |
| Organization name |
NIH
|
| Department |
NIA
|
| Lab |
Neurogenetics
|
| Street address |
9000 Rockville Pike
|
| City |
Bethesda |
| ZIP/Postal code |
20892 |
| Country |
USA |
| |
|
| Platform ID |
GPL6947 |
| Series (1) |
| GSE25580 |
Examination of impact of pathogenic mutations in LRRK2 upon gene expression in patient fibroblasts and HEK cells |
|
